This study was canied out on 40 egyptian epileptic patients, 20 on
valproate (30 - 50 mg/kg oral/day) and 20 patients were on carbamazepine
(20 - 40 mg/kg/oral/day).
Results of the present work demonstrated that some adverse effects
higher in valproate monotherapy than carbamazepine monotherapy as
tremors (10%), weight gain (20%) and appetite gain (10%), but others
were higher in carbamazepine monotherapy than valproate monotherapy
like headache (10%), rash (10%) and gastrointestinal troubles (15%).
Moreover some side effects occured with Carbamazepine monotherapy
like decreased lipido (5%) but not with valproate.
Also, there were no significant hematological changes either with valproate
or carbamazepine, Moreover, SGOT, SGPT and total bilirubin
were significantly elevated (p < 0.05) in valproate not with carbamazepine
monotherapy.
Finally, this study sufficiently provide useful informations of adverse
events when treating adult patients with monotherapy with valproate or
carbamazepine in a neurological out patient clinic in Benha University
Hospital.
|
